Trial
NCT03514017
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Merck Sharp & Dohme LLC; Janssen Scientific Affairs, LLC
Condition
Chronic Lymphocytic Leukemia
Intervention
Pembrolizumab
Why stopped
Funding unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-02